Prostate and bladder cancers affect millions of patients globally, yet validated biomarkers that can reliably predict treatment response, disease progression, and therapy resistance remain scarce in clinical practice. BRECISE seeks to change this by integrating cutting-edge technologies such as Next-Generation Sequencing (NGS), Artificial Intelligence (AI), and ex vivo drug testing to refine personalized treatment pathways.

BRECISE is structured around four core objectives: Clinical Validation of Biomarkers, Integration of NGS and AI, Ex Vivo Tumour Testing and Regulatory and Market Adoption.